Metastatic Non-Small Cell Lung Cancer Market to Surge with a Potential USD 45 Billion Valuation by 2032, Reveals New Comprehensive Analysis

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032" report has been added to's offering.

The metastatic Non-Small Cell Lung Cancer (NSCLC) treatment landscape is expected to undergo significant transformation, according to a new research report titled "Metastatic Non-Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2032." This extensive publication examines the evolving NSCLC market trends, epidemiology, and forecasted market size across seven major markets (7MM) - specifically focusing on the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan.

The analysis forecasts a staggering potential market size of approximately USD 45 billion by 2032 within the 7MM, fueled by increasing incident cases, the continuous uptake of immune checkpoint inhibitors, the emergence of new therapies, and a heightened awareness of genetic mutations such as KRAS, BRAF, and c-Met. The report provides a granular view of the treatment landscape, highlighting the shift towards targeted and immunotherapies and providing key insights into the impact of drug approvals such as Amgen's LUMAKRAS and the prospect of Antibody-Drug Conjugates (ADCs) in the NSCLC market.

The Metastatic NSCLC Market Forecast - Highlights:

  • A projected market size of ~USD 45 billion by 2032 in the 7MM, driven by innovative therapies and increasing disease prevalence.
  • Insightful real-world treatment trends indicating a substantial shift from systemic therapies to targeted treatments and immunotherapies.
  • KEYTRUDA and OPDIVO's market dominance and third-generation EGFR inhibitors such as TAGRISSO's expected stronghold within the EGFR- positive NSCLC market segment.
  • A detailed analysis of current and emerging therapeutic options, including an in-depth coverage of late-stage pipeline drugs and pivotal clinical trials.
  • A comprehensive view of the NSCLC epidemiology, segmented by histology, genetic alterations, stages, and treatment settings.

The report also delves into significant clinical and regulatory updates within the NSCLC landscape, including FDA drug approvals, innovations spotlighted at the American Society of Clinical Oncology (ASCO) 2023, and key milestones in drug development from industry players. Moreover, it provides a critical examination of current treatment practices and addresses the unmet medical needs within the landscape, paving the way for identifying the best market opportunities and evaluating the market's underlying potential.

Geographic coverage and the study period from 2019-2032 provide a comprehensive understanding of NSCLC's current state and future market projections. The report's insights are further enriched by Key Opinion Leader (KOL) views, reflecting real-world expertise and perspectives on the shifting NSCLC treatment paradigm.

The in-depth findings presented in this report are essential for stakeholders within the oncology segment to grasp the NSCLC market with clarity, enabling strategic decisions and fostering a competitive edge as the landscape advances towards innovative and patient-centric treatment solutions. With an expected surge in market size and the introduction of groundbreaking therapies, the future of NSCLC treatment is poised for a revolutionary leap in the upcoming decade.

Understanding Metastatic Non-Small Cell Lung Cancer and Its Market Outlook:

  1. An exploratory analysis of Non-small Cell Lung Cancer Overview, Diagnosis and Treatment Algorithm.
  2. A comprehensive assessment of current market dynamics, treatment approaches, and the anticipated market growth potentials.
  3. Patient population forecasts that provide a broad view of the evolving epidemiology pattern and its impact on the NSCLC market size.
  4. Insights from clinical and registrational updates of 2023, including anticipated drug approvals and their potential market impact.
  5. The rising prevalence of genetic mutations and their influence on treatment personalization in NSCLC.

This publication stands as an authoritative source for understanding the detailed market, patient, and clinical advancements within the metastatic Non-Small Cell Lung Cancer space. It provides a strategic compass for pharma companies, healthcare providers, and investors who are navigating this rapidly evolving oncology market.

A selection of companies mentioned in this report includes

  • AbbVie
  • Akeso Biopharma
  • Alethia Biotherapeutics
  • AnHeart Therapeutics
  • Arcus Biosciences
  • ArriVent BioPharma
  • AstraZeneca
  • BieGene
  • Bristol-Myers Squibb
  • Cullinan Oncology
  • Daiichi Sankyo
  • Dizal Pharmaceutical
  • Eli Lilly and Company
  • EQRx
  • Genentech
  • Gilead Sciences
  • GlaxoSmithKline
  • Gritstone bio
  • Hoffmann-La Roche
  • Immutep
  • Incyte
  • Jiangsu HengRui Medicine
  • Macrogenics
  • Merck Sharp & Dohme Corp
  • NeoTX Therapeutics
  • Novartis
  • Nuvalent
  • Pfizer
  • Regeneron Pharmaceuticals
  • Revolution Medicines
  • Roche (Genentech)
  • Sanofi
  • Shanghai Henlius Biotech
  • Taiho Pharma
  • Xcovery

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data